Drug Trial Radar · NCT05648357
A Study to Assess the Safety and Immune Response of Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in Participants Aged 65 Years and Older in India
Last checked: Nov 20, 2026Latest source record: Mar 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
250
Actual
Start
Dec 14, 2023
Primary completion
Feb 26, 2024
Study completion Feb 26, 2024
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Dec 13, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to gather additional evidence of the safety and immunogenicity of 1 dose of Fluarix Tetra (0.5 milliliter \[mL\]) (Northern Hemisphere (NH)2023-2024) in individuals aged 65 years and above to fulfill a post-approval condition imposed by the Indian regulatory authorities (CDSCO) for this age group in India.
Conditions
- Influenza, Human
Interventions
Fluarix Tetra VaccineBiological
A single dose of Fluarix Tetra vaccine administered intramuscularly (IM) on day 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Reporting Any Solicited Administration Site Adverse EventTime frame: Day 1 to Day 7
- Number of Participants Reporting Any Solicited Systemic EventsTime frame: Day 1 to Day 7
- Number of Participants Reporting Unsolicited Adverse Events (AEs)Time frame: Day 1 to Day 21
- Number of Participants Reporting Serious Adverse Events (SAEs)Time frame: Day 1 to Day 21
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Belagavi, India
GSK Investigational Site
Kattankulathur, India
GSK Investigational Site
Nashik, India
GSK Investigational Site
Nashik, India
GSK Investigational Site
Varanasi, India
GSK Investigational Site
Visakhapatnam, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.